STROBE Statement—Checklist of items that should be included in reports of case-control studies

	Item No	Recommendation	
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or	V
		the abstract	Page 1
		(b) Provide in the abstract an informative and balanced summary of	<b>V</b>
		what was done and what was found	Page 2,3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation	<b>V</b>
		being reported	Page 4
Objectives	3	State specific objectives, including any prespecified hypotheses	V
			Page 5
Methods	T		
Study design	4	Present key elements of study design early in the paper	V
			Page 5
Setting	5	Describe the setting, locations, and relevant dates, including periods of	V
		recruitment, exposure, follow-up, and data collection	Page 5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case	V
		ascertainment and control selection. Give the rationale for the choice of	Page 5-7
		cases and controls	
		(b) For matched studies, give matching criteria and the number of	V
		controls per case	Page 5-7
Variables	7	Clearly define all outcomes, exposures, predictors, potential	V
		confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 7
Data sources/	8*	For each variable of interest, give sources of data and details of	V
measurement		methods of assessment (measurement). Describe comparability of	Page 5-7
		assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	V
			Page 5, 13
Study size	10	Explain how the study size was arrived at	
Quantitative	11	Explain how quantitative variables were handled in the analyses. If	V
variables		applicable, describe which groupings were chosen and why	Page 5, 7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for	V
		confounding	Page 7, 8
		(b) Describe any methods used to examine subgroups and interactions	V
			Page 7, 8
		(c) Explain how missing data were addressed	Missing data
			were less
			than 5%
		(d) If applicable, explain how matching of cases and controls was	Not relevant
		addressed	
		(e) Describe any sensitivity analyses	Not relevant
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers	V
		potentially eligible, examined for eligibility, confirmed eligible,	Page 8
		included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	<b>√</b>

			Page 8,
			figure1
		(c) Consider use of a flow diagram	$\checkmark$
			Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical,	V
		social) and information on exposures and potential confounders	Page 8
		(b) Indicate number of participants with missing data for each variable	<b>√</b>
		of interest	Page 8
Outcome data	15*	Report numbers in each exposure category, or summary measures of	$\checkmark$
		exposure	Page 9, 10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted	V
		estimates and their precision (eg, 95% confidence interval). Make clear	Page 9, 10,
		which confounders were adjusted for and why they were included	table 3, and
			supplemental
			material
		(b) Report category boundaries when continuous variables were	V
		categorized	Page 8-10
		(c) If relevant, consider translating estimates of relative risk into	Not relevant
		absolute risk for a meaningful time period	

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Not relevant	
Discussion				
Key results	18	Summarise key results with reference to study objectives	V	
			Page 10-13	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or	$\checkmark$	
		imprecision. Discuss both direction and magnitude of any potential bias	Page 13, 14	
Interpretation	20	Give a cautious overall interpretation of results considering objectives,	$\checkmark$	
		limitations, multiplicity of analyses, results from similar studies, and other	Page 11-13	
		relevant evidence		
Generalisability	21	Discuss the generalisability (external validity) of the study results	$\checkmark$	
			Page 11-13	
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and,	Not relevant	
		if applicable, for the original study on which the present article is based		

<sup>\*</sup>Give information separately for cases and controls.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.